利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.069 秒)

    Use of Gonadorelin as a therapeutic agent
    1.
    发明授权
    Use of Gonadorelin as a therapeutic agent 失效
    使用Gonadorelin作为治疗剂

    公开(公告)号：US08349805B2

    公开(公告)日：2013-01-08

    申请号：US12677108

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A01N37/18 ,  A61K38/00 ,  A61P31/04 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

    CPC分类号： A61K38/12 ,  A61K38/09 ,  C07K14/58 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423

    摘要： The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilizate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2作为预防和/或治疗癌症，自身免疫疾病， 纤维化疾病，炎性疾病，神经变性疾病，传染病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干液或液体缓冲溶液或人造母乳制剂或含有Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-Leu-Arg-Pro-Gly- NH 2任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    Use of somatostatin-14 as a therapeutic agent
    2.
    发明授权
    Use of somatostatin-14 as a therapeutic agent 失效
    使用生长抑素-14作为治疗剂

    公开(公告)号：US08211856B2

    公开(公告)日：2012-07-03

    申请号：US12677813

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/00

    CPC分类号： A61K38/12 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423 ,  A61K2300/00

    摘要： The present invention is directed to the use of the peptide compound Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH作为预防和/ 或治疗癌症，自身免疫性疾病，纤维化疾病，炎症性疾病，神经变性疾病，感染性疾病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr- Phe-Thr-Ser-Cys-OH任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    USE OF A PEPTIDE AS A THERAPEUTIC AGENT
    3.
    发明申请
    USE OF A PEPTIDE AS A THERAPEUTIC AGENT 审中-公开
    使用作为治疗剂的肽

    公开(公告)号：US20100286028A1

    公开(公告)日：2010-11-11

    申请号：US12676906

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/18 ,  A61P31/04 ,  A61P29/00 ,  A61P11/00 ,  A61P35/00 ,  A61P9/00 ,  A61P3/00

    CPC分类号： A61K38/12 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423 ,  A61K2300/00

    摘要： The present invention is directed to the use of the peptide compound Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp- Pro-Lys-Arg-Leu-Tyr作为预防和/或治疗癌症，自身免疫性疾病，纤维化疾病，炎性疾病，神经变性疾病，感染性疾病，肺部疾病，心脏和血管疾病和代谢疾病的治疗剂。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Gly-Gly-Ser-Gly- Ala-Phe-Pro-Pro-Gly-His-Phe-Lys-Asp-Pro-Lys-Arg-Leu-Tyr任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    USE OF THE PEPTIDE ASN-ASP-ASP-CYS-GLU- LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR-GLY-CYS-LEU ALONE OR IN COMBINATION WITH THE PEPTIDE THR-THR-SER-GLN-VAL- ARG-PRO-ARG AS A THERAPEUTIC AGENT
    5.
    发明申请
    USE OF THE PEPTIDE ASN-ASP-ASP-CYS-GLU- LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR-GLY-CYS-LEU ALONE OR IN COMBINATION WITH THE PEPTIDE THR-THR-SER-GLN-VAL- ARG-PRO-ARG AS A THERAPEUTIC AGENT 审中-公开
    使用肽ASN-ASP-ASP-CYS-GLU-LEU-CYS-VAL-ASN-VAL-ALA-CYS-THR-GLY-CYS-LEU单独或与肽组合THR-THR-SER-GLN- VALAR ARG-PRO-ARG作为治疗药物

    公开(公告)号：US20100210553A1

    公开(公告)日：2010-08-19

    申请号：US12676908

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/10 ,  A61P25/28 ,  A61P37/00 ,  A61P11/00 ,  A61P31/04

    CPC分类号： A61K38/17 ,  A61K38/08 ,  A61K38/26 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/423 ,  A61K2300/00

    摘要： The present invention is directed to the use of the peptide compound Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH or its combination with the peptide Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH或其组合与 肽Thr-Thr-Ser-Gln-Val-Arg-Pro-Arg-OH作为预防和/或治疗癌症，自身免疫疾病，纤维化疾病，炎性疾病，神经变性疾病，感染性疾病，肺部疾病， 心脏和血管疾病和代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val- Ala-Cys-Thr-Gly-Cys-Leu-OH任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    USE OF RGDSPASSKP AND OPTIONALLY ANGIOTENSIN II AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG S. PNEUMONIAE INFECTIONS
    7.
    发明申请
    USE OF RGDSPASSKP AND OPTIONALLY ANGIOTENSIN II AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG S. PNEUMONIAE INFECTIONS 审中-公开
    RGDSPASSKP和OPENTALY ANGIOTENSIN II作为治疗EG细胞感染的治疗药物的使用

    公开(公告)号：US20100197603A1

    公开(公告)日：2010-08-05

    申请号：US12676927

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/08 ,  A61P35/00 ,  A61P3/02 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04

    CPC分类号： A61K38/095 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423

    摘要： The present invention is directed to the use of the peptide compound Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH作为预防和/或治疗癌症，自身免疫疾病， 纤维化疾病，炎性疾病，神经变性疾病，传染病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-Ala-Ser-Ser-Lys-Pro- OH任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。

    USE OF A DESLORELIN AND MASTOPARAN AS A THERAPEUTIC AGENT
    9.
    发明申请
    USE OF A DESLORELIN AND MASTOPARAN AS A THERAPEUTIC AGENT 审中-公开
    作为一种治疗药物，使用了脱乙酰丙酸和麻黄碱

    公开(公告)号：US20100184698A1

    公开(公告)日：2010-07-22

    申请号：US12677110

    申请日：2008-09-09

    申请人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    发明人： Dorian Bevec ,  Fabio Cavalli ,  Vera Cavalli ,  Gerald Bacher

    IPC分类号： A61K38/10 ,  A61K38/08 ,  A61P31/06 ,  A61P35/00 ,  A61P37/06 ,  A61P29/00 ,  A61P25/28 ,  A61P11/00 ,  A61P9/00 ,  A61P3/00

    CPC分类号： A61K38/08 ,  A61K38/1825 ,  Y02A50/385 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/422 ,  Y02A50/423

    摘要： The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.

    摘要翻译： 本发明涉及肽化合物Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt作为预防和/或治疗癌症，自身免疫疾病， 纤维化疾病，炎性疾病，神经变性疾病，传染病，肺部疾病，心脏和血管疾病以及代谢疾病。 此外，本发明涉及优选形式为冻干物或液体缓冲溶液或人造母乳制剂或含有Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro- NHEt任选与至少一种药学上可接受的载体，冷冻保护剂，冻干保护剂，赋形剂和/或稀释剂一起。